Diarrhea - Pipeline Review, H2 2020

July 2020 | 156 pages | ID: DAA06A1D26DEN
Global Markets Direct

Abstracts

Diarrhea - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2020, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.
Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 2, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 5 molecules, respectively.
Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Diarrhea - Overview
Diarrhea - Therapeutics Development
Diarrhea - Therapeutics Assessment
Diarrhea - Companies Involved in Therapeutics Development
Diarrhea - Drug Profiles
Diarrhea - Dormant Projects
Diarrhea - Discontinued Products
Diarrhea - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Diarrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Diarrhea - Pipeline by Albireo Pharma Inc, H2 2020
Diarrhea - Pipeline by Allergan Ltd, H2 2020
Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2020
Diarrhea - Pipeline by Boston Pharmaceuticals Inc, H2 2020
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2020
Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2020
Diarrhea - Pipeline by Glycosyn LLC, H2 2020
Diarrhea - Pipeline by Hilleman Laboratories Pvt Ltd, H2 2020
Diarrhea - Pipeline by Immuron Ltd, H2 2020
Diarrhea - Pipeline by Kaleido Biosciences Inc, H2 2020
Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2020
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2020
Diarrhea - Pipeline by MyBiotics Pharma Ltd, H2 2020
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2020
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2020
Diarrhea - Pipeline by Novartis AG, H2 2020
Diarrhea - Pipeline by OnQuality Pharmaceutical USA LLC, H2 2020
Diarrhea - Pipeline by Orphomed Inc, H2 2020
Diarrhea - Pipeline by Pharmascience Inc, H2 2020
Diarrhea - Pipeline by Prokarium Ltd, H2 2020
Diarrhea - Pipeline by Protagonist Therapeutics Inc, H2 2020
Diarrhea - Pipeline by RaQualia Pharma Inc, H2 2020
Diarrhea - Pipeline by Rebiotix Inc, H2 2020
Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2020
Diarrhea - Pipeline by RxBio Inc, H2 2020
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2020
Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2020
Diarrhea - Pipeline by Syntiron LLC, H2 2020
Diarrhea - Pipeline by Yisheng Biopharma Co Ltd, H2 2020
Diarrhea - Pipeline by Zhiyi Pharmaceuticals Inc, H2 2020
Diarrhea - Dormant Projects, H2 2020
Diarrhea - Dormant Projects, H2 2020 (Contd..1), H2 2020
Diarrhea - Dormant Projects, H2 2020 (Contd..2), H2 2020
Diarrhea - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diarrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Albireo Pharma Inc
Allergan Ltd
AzurRx BioPharma Inc
Boston Pharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Cosmo Pharmaceuticals NV
DiscoveryBiomed Inc
Glycosyn LLC
Hilleman Laboratories Pvt Ltd
Immuron Ltd
Kaleido Biosciences Inc
Kuhnil Pharmaceutical Co Ltd
Miyarisan Pharmaceutical Company Ltd
MyBiotics Pharma Ltd
Napo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
OnQuality Pharmaceutical USA LLC
Orphomed Inc
Pharmascience Inc
Prokarium Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
Rebiotix Inc
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Synthetic Biologics Inc
Syntiron LLC
Yisheng Biopharma Co Ltd
Zhiyi Pharmaceuticals Inc